Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+metastatic breast cancer

被引：0
|
作者：
Gajria, D. [1 ]
King, T. [1 ]
Pannu, H. [1 ]
Sakr, R. [1 ]
Modi, S. [1 ]
Drullinsky, P. [1 ]
Syldor, A. [1 ]
Path, S. [1 ]
Seidman, A. [1 ]
Norton, L. [1 ]
Rosen, N. [1 ]
Hudis, C. [1 ]
Chandarlapaty, S. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P5-18-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-18-04
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Targeting multiple pathways in breast cancer: Androgen receptor, HER2, and mTOR
    Gordon, Michael A.
    D'Amato, Nicholas
    Gu, Haihua
    Wong, Darren
    Elias, Anthony
    Richer, Jennifer K.
    CANCER RESEARCH, 2015, 75
  • [42] HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab
    Ithimakin, Suthinee
    Day, Kathleen C.
    Malik, Fayaz
    Zen, Qin
    Dawsey, Scott J.
    Bersano-Begey, Tom F.
    Quraishi, Ahmed A.
    Ignatoski, Kathleen Woods
    Daignault, Stephanie
    Davis, April
    Hall, Christopher L.
    Palanisamy, Nallasivam
    Heath, Amber N.
    Tawakkol, Nader
    Luther, Tahra K.
    Clouthier, Shawn G.
    Chadwick, Whitney A.
    Day, Mark L.
    Kleer, Celina G.
    Thomas, Dafydd G.
    Hayes, Daniel F.
    Korkaya, Hasan
    Wicha, Max S.
    CANCER RESEARCH, 2013, 73 (05) : 1635 - 1645
  • [43] Targeting HER2 heterogeneity in breast cancer
    Hamilton, Erika
    Shastry, Mythili
    Shiller, S. Michelle
    Ren, Rongqin
    CANCER TREATMENT REVIEWS, 2021, 100
  • [44] Targeting HER2/3 in Breast Cancer
    Hepner A.
    Modi S.
    Jhaveri K.
    Current Breast Cancer Reports, 2017, 9 (2) : 61 - 69
  • [45] Targeting HER2 beyond breast cancer
    Bhatnagar, Sanchita
    Tushir-Singh, Jogender
    MOLECULAR & CELLULAR ONCOLOGY, 2019, 6 (03):
  • [46] Targeting HER2 for the Treatment of Breast Cancer
    Rimawi, Mothaffar F.
    Schiff, Rachel
    Osborne, C. Kent
    ANNUAL REVIEW OF MEDICINE, VOL 66, 2015, 66 : 111 - 128
  • [47] HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: Implications for efficacy of adjuvant trastuzumab
    Maiik, Fayaz
    Ithimakin, Suthinee
    Day, Kathleen
    Ignatoski, Kathy
    Zen, Qin
    Thomas, Dafydd
    Bersano, Tom
    Dawsey, Scott
    Hall, Christopher
    Davis, April
    Quraishi, Ahmed A.
    Tawakkol, Nader
    Clouthier, Shawn G.
    Day, Mark
    Hayes, Daniel F.
    Korkaya, Hasan
    Wicha, Max S.
    CANCER RESEARCH, 2012, 72
  • [48] Trastuzumab as a preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancer
    Lion, Maeva
    Harle, Alexandre
    Salleron, Julia
    Ramacci, Carole
    Campone, Mario
    Merlin, Jean-Louis
    ONCOLOGY LETTERS, 2016, 12 (03) : 2028 - 2032
  • [49] LEVEL OF HER2/NEU GENE (HER2) AMPLIFICATION IN PRIMARY AND METASTATIC SITES IN HER2-POSITIVE METASTATIC BREAST CANCER AND RESPONSE TO TRASTUZUMAB(T)-BASED THERAPY
    Gullo, G.
    Bettio, D.
    Zuradelli, M.
    Giordano, L.
    Masci, G.
    Bareggi, C.
    Salvini, P.
    Venci, A.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 101 - 101
  • [50] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
    Elisa Van Raemdonck
    G. Floris
    P. Berteloot
    A. Laenen
    I. Vergote
    H. Wildiers
    K. Punie
    P. Neven
    Breast Cancer Research and Treatment, 2021, 185 : 183 - 194
12345